HER2-Neu Gene Testing in Gastric Cancer by Immunohistochemistry in Tunisian Patient�s Samples
Received Date: Nov 07, 2016 / Accepted Date: Feb 21, 2017 / Published Date: Feb 27, 2017
Abstract
Immunohistochemical (IHC) testing for HER2/neu is becoming the standard of care for guiding the adjuvant treatment of gastric carcinoma with trastuzumab. Up to now, gastric cancer has been considered the most commonly diagnosed tumors leading to death. In this study, we evaluate the detection of HER2 expression by IHC in Tunisian patients with gastric cancer according to the international consensus. A total of 84 tumor specimens was assessed for HER2 expression by immunohistochemistry (IHC) using the antibodies HercepTest™. Doubtful IHC results (IHC 2+) were resolved by HER2 Chromogenic in situ hybridization (CISH). Thus, 10.5% of samples were HER2-positive (3+), 8.3% having a negative score IHC, Her2-Neu (+1) and 3.6% to be a dubious immunostaining Her2-Neu (2+).
Keywords: HER2-Neu Gene; Gastric cancer; Trastazumab; Immunohistochemistry; In Situ Hybridization
Citation: Gharsalli T, Bouazzi H, Aiwasiyah B, Sassi M, Sriha B (2017) HER2-Neu Gene Testing in Gastric Cancer by Immunohistochemistry in Tunisian Patient’s Samples. J Cancer Diagn 2: 110. Doi: 10.4172/2476-2253.1000110
Copyright: © 2017 Gharsalli T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
ÌìÃÀ´«Ã½ Access Journals
Article Tools
Article Usage
- Total views: 6160
- [From(publication date): 0-2017 - Jan 10, 2025]
- Breakdown by view type
- HTML page views: 5347
- PDF downloads: 813
